Increased platelet destruction in infancy and childhood.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000743:Anemia, Hemolytic / Q000097:blood / Q000150:complications; D000818:Animals; D001327:Autoimmune Diseases / Q000097:blood / Q000150:complications; D001792:Blood Platelets / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D004211:Disseminated Intravascular Coagulation / Q000097:blood; D004761:Enterocolitis, Pseudomembranous / Q000097:blood / Q000150:complications; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood / Q000150:complications; D006391:Hemangioma / Q000097:blood / Q000150:complications; D006463:Hemolytic-Uremic Syndrome / Q000097:blood; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000097:blood; D010789:Phototherapy / Q000009:adverse effects; D010976:Platelet Count; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D011817:Rabbits; D013921:Thrombocytopenia / Q000151:congenital / Q000209:etiology* / Q000276:immunology; D014635:Valproic Acid / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D014635:Valproic Acid